Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Neuropathic Pain
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
Comprehensive Huntington's Disease CRO Solutions for Drug Discovery
Advance the development of targeted therapeutics for Huntington's Disease with Cyagen's specialized research platform. We empower scientists worldwide with validated knock-in models, end-to-end CRO services, and expert strategy to accelerate the discovery of novel HD treatments.
An Integrated Approach to HD Research & Its Challenges

As a fatal genetic disorder characterized by progressive motor, cognitive, and psychiatric symptoms, HD carries a heavy burden with no available cure. Researchers face key bottlenecks, including the need for models that accurately reflect the progressive nature of the disease and the challenge of establishing robust, longitudinal assessments of therapeutic efficacy.

To overcome these hurdles, Cyagen has developed a specialized and integrated research platform. Our portfolio of knock-in models that closely mimic the human genetic condition, combined with the comprehensive in vivo and in vitro services detailed below, provides the critical tools scientists need to establish robust assessments and accelerate their HD discovery programs.
{{ item.title }}
{{static_tabs[0].title}}
Our comprehensive portfolio of Huntington's Disease (HD) models is centered on knock-in (KI) technology to closely mimic the human genetic condition. The table below includes both our validated, ready-to-use models for immediate deployment, and our advanced R&D platform for key disease modifiers, available for custom projects and collaborative research.
Catalog Number Name Base Strain Research Application Action
{{ value.product_num || "--" }} {{ value.product_name || "--" }} {{ value.product_strain || "--" }}
;
Inquire
+
Previous Page
Next Page
Can't find the model you need?
Explore hundreds of additional off-the-shelf neuroscience models in our MouseAtlas database, or partner with our scientific team to develop a custom-engineered model tailored to your exact research specifications.
{{static_tabs[1].title}}
Precision Drug Administration
Our team is highly experienced in administration methodologies critical for HD research, including systemic and direct CNS delivery routes for novel therapeutics like ASOs and small molecules.
  • Systemic Delivery: Intravenous (tail vein), Intraperitoneal, Subcutaneous, Oral Gavage, etc.
  • CNS-Targeted Delivery: Stereotactic brain injection (e.g., into the striatum), Intrathecal injection, Intraventricular injection.
Neurobehavioral Assessment for HD
We provide a focused suite of behavioral paradigms essential for evaluating the core motor, cognitive, and psychiatric-like symptoms associated with Huntington's Disease.
Behavioral Domain Recommended Tests for HD Research Function Tested
Motor Function & Coordination Rotarod Test Motor coordination, balance, and motor learning deficits
Grip Strength Muscle strength and progressive motor decline
Balance Beam Fine motor coordination and balance
Spontaneous Activity & Anxiety Open Field Test Locomotor activity (hyper/hypo-activity), anxiety-like behavior
Cognitive Function Y-Maze Spatial working memory
{{static_tabs[2].title}}
We offer a specialized suite of analytical services to quantify the core pathological hallmarks of Huntington's Disease and to elucidate the molecular mechanisms of your therapeutic candidates.
Analysis Category Specific Services Key Applications & Targets in HD Research
Pathology & Biomarker Analysis Histology & IHC/IF Visualize and quantify mutant Huntingtin (mHTT) aggregates (using antibodies like EM48) and assess neuronal loss, particularly in the striatum and cortex.
ELISA & Immunoassays Accurately quantify levels of soluble and insoluble mutant Huntingtin (mHTT) in brain tissue, CSF, and other biological samples to measure target engagement.
Gene & Protein Expression Western Blot Assess the expression levels of total and mutant Huntingtin (HTT) protein, a critical readout for evaluating the efficacy of HTT-lowering therapeutics (e.g., ASOs, siRNAs).
RT-PCR & qPCR Analyze the expression of the HTT gene to confirm target engagement and investigate downstream transcriptional changes.
Case Studies
Case Study 1: FVB-hHTT Q150 KI: Profiling Progressive HD-like Deficits
{{ item.label }}
{{v2.label}}
{{item.context}}
{{v2.context}}
{{item.title}}
{{ item.context }}
{{v2.title}}
Case Study 2: FVB-HTT KI(nQ): Validating the nQ Control Model
{{ item.label }}
{{v2.label}}
{{item.context}}
{{v2.context}}
{{item.title}}
{{ item.context }}
Why Partner with Cyagen?
Clinically Relevant Models
Gain access to validated, knock-in models that exhibit progressive, age-dependent phenotypes highly relevant to the human condition.
Integrated Efficacy Platform
Utilize our one-stop services—from longitudinal behavioral monitoring to terminal pathological and biochemical analysis.
Data-Driven Decision Support
Our stringent quality control and commitment to reproducibility deliver reliable data for your project decisions.
Expert-Led Study Design
Collaborate with our senior scientists for end-to-end support, from model selection to customized protocol design.
Related Resources
Events & Webinars
Beyond the mouse: Accelerating Drug Discovery for Obesity & T2D with HUGO-GT™
View Details
Promotional Campaign
Flash Drop — Ready-to-Ship KO/cKO Mice
View Details
Blogs & Insights
Why Eli Lilly is Targeting Nav1.8 and MNK for Next-Gen Pain Therapeutics
View Details
Resource Valut
Development of Fully Human Anti-ACVR2A Antibodies with Enhanced Selectivity and Favorable Pharmacokinetics for Metabolic and Muscle Disorders
View Details
Request a Preclinical CRO Services Consultation
Partner with Cyagen to advance your preclinical studies. Share your project goals with us and receive customized support.
Inquiry Details
Main Area of Research
Service(s) of Interest
Project Details
How did you hear about us?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research